Effect of combined exercise therapy and isoflavone supplementation on prevention of osteoporosis

Not Applicable

Completed

• Conditions: Musculoskeletal Diseases; Osteoporosis

• Registration Number: ISRCTN76916228
• Lead Sponsor: niversity of Saskatchewan (Canada)

Brief Summary

1. 2013 results in https://www.ncbi.nlm.nih.gov/pubmed/23165609 (added 01/02/2019)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-09
• Study Completion: 2008-05-30
• Last Update Posted: 4 March 2019

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 360

Inclusion Criteria

Post-menopausal women (age range of approximately 45 to 70 years)

Exclusion Criteria

1. Diagnosed osteoporosis
2. Previous fragility fractures
3. Above normal bone mineral density (equal to or above the young adult mean)
4. Breast or endometrial cancers
5. Women taking bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators, parathyroid hormone (PTH), or calcitonin in the past 12 months
6. Taking corticosteroids or diuretics
7. Diagnosed Crohn?s Disease and Cushing Disease
8. Women with allergies to soy
9. Severe osteoporosis
10. Smokers
11. Currently participating in vigorous exercise programs

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umbar spine bone mineral density

Secondary Outcome Measures

Name	Time	Method
<br> 1. Bone mineral density of the proximal femur and whole body<br> 2. Bone quality of the calcaneus<br> 3. Geometry the proximal femur<br> 4. Lean tissue mass<br> 5. Fat mass<br> 6. Body mass index<br> 7. Waist girth<br> 8. Skinfolds<br> 9. Blood lipids<br> 10. Breast density<br> 11. Endometrial thickness<br> 12. Menopausal symptoms<br> 13. Physical activity levels<br> 14. Muscular strength<br> 15. Self-paced walking ability<br> 16. Balance and flexibility<br>